Cline Scientific: Board members and major investors exercise held warrants of series 2020/2021
Cline Scientific announces that persons on the Board of Directors, executive management and major owners who hold warrants series 2020/2021 have chosen to exercise their holdings. Holders of warrants have the right to subscribe for one (1) new share in Cline Scientific for each owned warrant of series 2020/2021 at a price of SEK 3.38 per share. The exercise period for warrants runs between 2 - 12 March 2021.
The following parties have declared their intention to use their warrants
- CEO Patrik Sundh
- Chairman Torleif Möllerström
- Stiftelsen Chalmers Tekniska Högskola
- Financial advisor Företagsfinansiering Fyrstad (Mats Ekberg)
Application form with instructions for payment is available on the Company's website www.clinescientific.com and on Aktieinvest FK AB's website https://www.aktieinvest.se/.
Full terms for the warrants were included as part of the memorandum published in connection with the rights issue, which was published on May 8, 2020. The memorandum is available at www.clinescientific.com.
For more information, please contact:
Patrik Sundh, CEO
Phone: +46 703-585 088
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase